extranodal NK/T cell lymphoma
Conditions
Interventions
treatment arm:combination of pegaspargase and concurrent radiotherapy
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with histology and immunohistochemical confirm primary upper respiratory (include nasal cavity, nasopharynx, oropharynx, oral cavity and larynx) NK/T cell lymphoma; 2. Stage IE and IIE; 3. Patients who have not been treated by any antitumor approach; 4. Patient aged 18-75 years; 5. ECOG performance status 0-2; 6. Have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Women in pregnancy or lactation, or patients in child-bearing period who would not conduct birth control; 2. Patients have been diagnosed to have other malignant tumors (except skin basal cell carcinoma and cervical carcinoma in situ) in five years; 3. Organ transplant patients; 4. Patients who have participated other drug clinical trials in 30 days; 5. Patients had main organ surgery 1.5*upper limit of normal; Transaminases (ALT or AST) >2.5*upper limit of normal]. Abnormal renal function (serum creatinine > 1.5*upper limit of normal); Absolute neutrophil count < 1.5*10^9/L, platelet count <80*10^9/L, hemoglobin <90 g/L; 9. Patients with mental disorder or patients could not provide inform consent; 10. Drug and alcohol abuse that would affect the evaluation for the test results; 11. Any other condition which is inappropriate for the study in the opinion of the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| two-year progression free survival (PFS) rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| two-year overall survival rate;safety profile;complete response rate; | — |
Countries
China
Contacts
Public ContactLu Yue
Outcome results
None listed